In this April 10, 2020 photo, a staff member shows an inactivated COVID-19 vaccine sample at a production unit of the China National Biotec Group. (PHOTO / XINHUA)
BEIJING – An inactivated COVID-19 vaccine developed by China has started phase-3 clinical trials in Argentina, according to its developer China National Biotec Group (CNBG), which is affiliated to Sinopharm.
The launch ceremony of the phase-3 clinical trials was held in Beijing Friday after the CNBG obtained the certificate of approval for the process.
This is an achievement brought about by CNBG's international cooperation in a bid to develop a COVID-19 vaccine.
The CNBG will work together with a company in Argentina to promote research and development related to the inactivated vaccine.
Liu Jingzhen, chairman of Sinopharm, said the phase-3 clinical trials will help fight the epidemic and contribute to the building of a community of health for all.
Copyright 1995 - 2021. All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily. Without written authorization from China Daily, such content shall not be republished or used in any form.
HONG KONG NEWS